Yarrow Bioscience (YARW) Cash & Current Investments (2016 - 2026)

Yarrow Bioscience (YARW) has 11 years of Cash & Current Investments data on file, last reported at $24.9 million in Q1 2026.

• Quarterly Cash & Current Investments fell 50.41% year-over-year to $24.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.9 million (down 50.41% YoY) and the FY2025 annual result came in at $29.0 million, down 52.84% from the prior year.
• Cash & Current Investments retreated to $24.9 million in Q1 2026, from $29.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $86.0 million in Q1 2024 to a low of $54000.0 in Q3 2023.
• A 5-year average of $40.7 million and a median of $41.2 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments sank 99.87% — and 2024, when it surged 129872.22%.
• Tracing YARW's Cash & Current Investments over 5 years: stood at $67000.0 in 2022, then surged by 93462.69% to $62.7 million in 2023, then decreased by 1.87% to $61.5 million in 2024, then sank by 52.84% to $29.0 million in 2025, then slipped by 14.07% to $24.9 million in 2026.
• The last three Cash & Current Investments figures came in at $24.9 million (Q1 2026), $29.0 million (Q4 2025), and $39.6 million (Q2 2025), per Business Quant data.